151 related articles for article (PubMed ID: 24900329)
41. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration.
White JR; Lee JM; Dede K; Imburgia CS; Jurewicz AJ; Chan G; Fornwald JA; Dhanak D; Christmann LT; Darcy MG; Widdowson KL; Foley JJ; Schmidt DB; Sarau HM
J Biol Chem; 2000 Nov; 275(47):36626-31. PubMed ID: 10969084
[TBL] [Abstract][Full Text] [Related]
42. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Dow RL; Li JC; Pence MP; Gibbs EM; LaPerle JL; Litchfield J; Piotrowski DW; Munchhof MJ; Manion TB; Zavadoski WJ; Walker GS; McPherson RK; Tapley S; Sugarman E; Guzman-Perez A; DaSilva-Jardine P
ACS Med Chem Lett; 2011 May; 2(5):407-12. PubMed ID: 24900321
[TBL] [Abstract][Full Text] [Related]
43. Up-regulation of CCR2 chemokine receptor expression and increased susceptibility to the multitropic HIV strain 89.6 in monocytes exposed to glucocorticoid hormones.
Penton-Rol G; Cota M; Polentarutti N; Luini W; Bernasconi S; Borsatti A; Sica A; LaRosa GJ; Sozzani S; Poli G; Mantovani A
J Immunol; 1999 Sep; 163(6):3524-9. PubMed ID: 10477627
[TBL] [Abstract][Full Text] [Related]
44. Isolation and structures of novel fungal metabolites as chemokine receptor (CCR2) antagonists.
Herath KB; Jayasuriya H; Ondeyka JG; Polishook JD; Bills GF; Dombrowski AW; Cabello A; Vicario PP; Zweerink H; Guan Z; Singh SB
J Antibiot (Tokyo); 2005 Nov; 58(11):686-94. PubMed ID: 16466022
[TBL] [Abstract][Full Text] [Related]
45. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration.
Auvynet C; Baudesson de Chanville C; Hermand P; Dorgham K; Piesse C; Pouchy C; Carlier L; Poupel L; Barthélémy S; Felouzis V; Lacombe C; Sagan S; Chemtob S; Quiniou C; Salomon B; Deterre P; Sennlaub F; Combadière C
FASEB J; 2016 Jun; 30(6):2370-81. PubMed ID: 26979087
[TBL] [Abstract][Full Text] [Related]
46. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
Borthwick AD; Liddle J
Med Res Rev; 2011 Jul; 31(4):576-604. PubMed ID: 20027670
[TBL] [Abstract][Full Text] [Related]
47.
Lesage A; Gibson C; Marceau F; Ambrosi HD; Saupe J; Katzer W; Loenders B; Charest-Morin X; Knolle J
Front Pharmacol; 2020; 11():916. PubMed ID: 32636746
[TBL] [Abstract][Full Text] [Related]
48. The discovery of novel cyclohexylamide CCR2 antagonists.
Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
[TBL] [Abstract][Full Text] [Related]
49. Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
Arbuckle W; Baker J; Barn D; Bingham M; Brown A; Buchanan K; Craighead M; Goodwin R; Goutcher S; Kiczun M; Lyons A; Milne R; Montgomery B; Napier S; Presland J; Sloan H; Turnbull Z; Wishart G
Bioorg Med Chem Lett; 2011 Aug; 21(15):4622-8. PubMed ID: 21700453
[TBL] [Abstract][Full Text] [Related]
50. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL.
Han KH; Tangirala RK; Green SR; Quehenberger O
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1983-91. PubMed ID: 9848893
[TBL] [Abstract][Full Text] [Related]
51. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.
Gever JR; Soto R; Henningsen RA; Martin RS; Hackos DH; Panicker S; Rubas W; Oglesby IB; Dillon MP; Milla ME; Burnstock G; Ford AP
Br J Pharmacol; 2010 Jul; 160(6):1387-98. PubMed ID: 20590629
[TBL] [Abstract][Full Text] [Related]
52. Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Carter PH; Brown GD; King SR; Voss ME; Tebben AJ; Cherney RJ; Mandlekar S; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Decicco CP
Bioorg Med Chem Lett; 2012 May; 22(9):3311-6. PubMed ID: 22475558
[TBL] [Abstract][Full Text] [Related]
53. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
[TBL] [Abstract][Full Text] [Related]
55. Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig.
Hay DW; Muccitelli RM; Vickery-Clark LM; Novak LS; Osborn RR; Gleason JG; Yodis LA; Saverino CM; Eckardt RD; Sarau HM
Pulm Pharmacol; 1991; 4(3):177-89. PubMed ID: 1668219
[TBL] [Abstract][Full Text] [Related]
56. The obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2).
Maffei M; Funicello M; Vottari T; Gamucci O; Costa M; Lisi S; Viegi A; Ciampi O; Bardi G; Vitti P; Pinchera A; Santini F
BMC Biol; 2009 Dec; 7():87. PubMed ID: 20017911
[TBL] [Abstract][Full Text] [Related]
57. In vivo MR evaluation of the effect of the CCR2 antagonist on macrophage migration.
Lee Y; Ryu JW; Chang H; Sohn JY; Lee KW; Woo CW; Kang HJ; Jeong SY; Choi EK; Lee JS
Magn Reson Med; 2010 Jul; 64(1):72-9. PubMed ID: 20572147
[TBL] [Abstract][Full Text] [Related]
58. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.
Cherney RJ; Mo R; Meyer DT; Nelson DJ; Lo YC; Yang G; Scherle PA; Mandlekar S; Wasserman ZR; Jezak H; Solomon KA; Tebben AJ; Carter PH; Decicco CP
J Med Chem; 2008 Feb; 51(4):721-4. PubMed ID: 18232650
[TBL] [Abstract][Full Text] [Related]
59. Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Yang L; Zhou C; Guo L; Morriello G; Butora G; Pasternak A; Parsons WH; Mills SG; MacCoss M; Vicario PP; Zweerink H; Ayala JM; Goyal S; Hanlon WA; Cascieri MA; Springer MS
Bioorg Med Chem Lett; 2006 Jul; 16(14):3735-9. PubMed ID: 16698264
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.
Lim JW; Oh Y; Kim JH; Oak MH; Na Y; Lee JO; Lee SW; Cho H; Park WK; Choi G; Kang J
Bioorg Med Chem Lett; 2010 Apr; 20(7):2099-102. PubMed ID: 20223662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
